var data={"title":"Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5651?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-patient-drug-information\" class=\"drug drug_patient\">see &quot;Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Patient drug information&quot;</a> and <a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10514505\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Thromboembolic events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Thromboembolic events have been reported during postmarketing surveillance following infusion of anti-inhibitor coagulant complex, particularly following the administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving anti-inhibitor coagulant complex for signs and symptoms of thromboembolic events.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135834\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>FEIBA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135835\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>FEIBA NF</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135851\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Activated Prothrombin Complex Concentrate (aPCC);</li>\n      <li>\n        Antihemophilic Agent;</li>\n      <li>\n        Blood Product Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135836\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Anti-inhibitor coagulant complex (Human) contains mainly non-activated therapeutic levels of factors II, IX, and X and mainly <i>activated</i> factor VII</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Control and prevention of bleeding episodes in patients with hemophilia:</b> IV: <b>Note:</b> Considered a first-line treatment when factor VIII inhibitor titer is &gt;5 Bethesda units (BU) (antihemophilic factor may be preferred when titer &lt;5 BU)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing guidelines:</b> 50 to 100 units/kg/dose. Dosage and duration of treatment depend on the location and extent of bleeding and clinical condition of the patient.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Joint hemorrhage:</i> 50 to 100 units/kg every 12 hours until pain and acute disabilities are improved (maximum: 100 units/kg/dose; 200 units/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mucous membrane bleeding:</i> 50 to 100 units/kg every 6 hours for at least 1 day or until bleeding is resolved (maximum: 100 units/kg/dose; 200 units/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Soft tissue hemorrhage (eg, retroperitoneal bleed):</i> 100 units/kg every 12 hours until resolution of bleed (maximum: 100 units/kg/dose; 200 units/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Other severe hemorrhage (eg, intracranial hemorrhage):</i> 100 units/kg every 6 to 12 hours; continue until resolution of bleed (maximum: 100 units/kg/dose; 200 units/kg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Perioperative management:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Preoperative: 50 to 100 units/kg (single dose) administered immediately prior to surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postoperative: 50 to 100 units/kg every 6 to 12 hours until resolution of bleed and healing is achieved (maximum: 100 units/kg/dose; 200 units/kg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Routine prophylaxis:</i> 85 units/kg every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemorrhage (moderate-to-severe) due to acquired hemophilia (off-label use):</b> IV: <b>Optimal dosing has not been established:</b> 50 to 100 units/kg every 8 to 12 hours until bleeding controlled has been suggested; may continue for 24 to 72 hours based on site, type, and severity of bleeding (maximum: 200 units/kg/day) (Huth-Kuhne 2009, Sallah 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intracranial hemorrhage associated with non-vitamin K antagonist anticoagulants (off-label use):</b> IV: NCS/SCCM (Frontera 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral direct factor Xa inhibitor-mediated (apixaban, edoxaban, rivaroxaban):</i> 50 units/kg if ICH occurred within 3 to 5 terminal half-lives of drug exposure or when liver failure co-exists.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Direct thrombin inhibitor-mediated (argatroban, dabigatran [if idarucizumab unavailable], bivalirudin, desirudin):</i> 50 units/kg if direct thrombin inhibitor was administered within a period of 3 to 5 half-lives prior and there is no evidence of renal failure <b>or</b> there is renal impairment leading to drug exposure beyond 3 to 5 half-lives.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pentasaccharide-mediated (fondaparinux)</i>\n      <i>(full therapeutic dose):</i> 20 units/kg. <b>Note:</b> In patients receiving fondaparinux for venous thromboembolism prophylaxis (ie, not a full therapeutic dose), the NCS/SCCM guidelines suggest <i>against</i> reversal unless there is evidence of bioaccumulation or impaired clearance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Life-threatening bleeding associated with non-vitamin K antagonist anticoagulation (off-label use):</b> IV: <b>Optimal dosing has not been established.</b> Based on multiple case reports with various types of hemorrhage due to either dabigatran or rivaroxaban, a dosage range of 25 to 100 units/kg has been used (Dager 2013; Faust 2014; Kiraly 2013; Maurice-Szamburski 2014; Neyens 2014; Schulman 2014). In 1 case study, after administration of 26 units/kg, an additional dose of 16 units/kg was administered for a concern of rebleeding (Dager 2013). <b>Note:</b> The use of anti-inhibitor coagulant complex (FEIBA, activated 4-factor PCC) may be associated with a higher risk of thrombosis compared to nonactivated PCCs especially with higher doses; monitor closely for arterial and venous thrombosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135846\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Anti-inhibitor coagulant complex (Human) contains mainly non-activated therapeutic levels of factors II, IX, and X and mainly <i>activated</i> factor VII</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Control and prevention of bleeding episodes in patients with hemophilia:</b> Infants, Children, and Adolescents: IV: <b>Note:</b> Considered a first-line treatment when factor VIII inhibitor titer is &gt;5 Bethesda units (BU) (antihemophilic factor may be preferred when titer &lt;5 BU).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing guidelines:</b> 50 to 100 units/kg per dose. Dosage and duration of treatment depend on the location and extent of bleeding and clinical condition of the patient.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Joint hemorrhage: </i>50 to 100 units/kg every 12 hours until pain and acute disabilities are improved (maximum: 100 units/kg/dose; 200 units/kg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mucous membrane bleeding: </i>50 to 100 units/kg every 6 hours for at least 1 day or until bleeding is resolved (maximum: 100 units/kg/dose; 200 units/kg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Soft tissue hemorrhage (eg, retroperitoneal bleed): </i>100 units/kg every 12 hours until resolution of bleed (maximum: 100 units/kg/dose; 200 units/kg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other severe hemorrhage (eg, intracranial hemorrhage):</i> 100 units/kg every 6 to 12 hours; continue until resolution of bleed (maximum: 100 units/kg/dose; 200 units/kg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Perioperative management:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preoperative: 50 to 100 units/kg (single dose) administered immediately prior to surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postoperative: 50 to 100 units/kg every 6 to 12 hours until resolution of bleed and healing is achieved (maximum: 100 units/kg/dose; 200 units/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Routine prophylaxis:</i> 85 units/kg every other day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135837\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673193\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673194\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135824\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FEIBA: 500 units (1 ea); 1000 units (1 ea); 2500 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135810\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573580\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FEIBA strengths expressed in terms of Factor VIII inhibitor bypassing activity with nominal strength values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135826\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV injection or infusion only; maximum infusion rate: 2 units/kg/minute. A syringe pump may be used to control the rate of administration. Use plastic luer lock syringes (anti-inhibitor coagulant complex may stick to the surface of all-glass syringes); do not administer in the same tubing or container with other medications. Following reconstitution, complete infusion within 3 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135825\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemorrhage in patients with hemophilia:</b> Control and prevention of bleeding episodes in patients with hemophilia A and B with inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perioperative bleeding management in patients with hemophilia:</b> Perioperative bleeding management in patients with hemophilia A and B with inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Routine prophylaxis of bleeding events in patients with hemophilia:</b> Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A and B with inhibitors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734780\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acquired hemophilia with factor VIII or factor IX inhibitor titers &gt;5 Bethesda units (BU); Intracranial hemorrhage associated with non-vitamin K antagonist anticoagulants; Life-threatening bleeding associated with non-vitamin K antagonist anticoagulants</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135816\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cerebrovascular accident (embolic/thrombotic stroke), chest discomfort, chest pain, decreased blood pressure, flushing, hypertension, hypotension, myocardial infarction, pulmonary embolism, tachycardia, thromboembolism, thrombosis (arterial thrombosis, venous thrombosis)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Chills, dizziness, drowsiness, headache, hypoesthesia (including facial), malaise, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus, skin rash, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distress, diarrhea, dysgeusia, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Angioedema, hypersensitivity reaction (including anaphylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: Antibody development (anamnestic response)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchospasm, cough, dyspnea, wheezing </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135828\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known anaphylactic or severe hypersensitivity to anti-inhibitor coagulant complex or any component of the formulation, including factors of the kinin generating system; disseminated intravascular coagulation (DIC); acute thrombosis or embolism (including myocardial infarction)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135813\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity and allergic reactions (including severe and systemic reactions [eg, anaphylaxis with urticaria and angioedema, bronchospasm, circulatory shock]) have been observed following administration. Discontinue immediately with signs/symptoms of severe hypersensitivity reactions and provide appropriate supportive care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Infusion reactions (eg, chills, pyrexia, hypertension) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: Thromboembolic events (including venous thrombosis, pulmonary embolism, MI, and stroke) have been reported following administration of anti-inhibitor coagulant complex, particularly with administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving anti-inhibitor coagulant complex for signs and symptoms of thromboembolic events,</b> especially if more than 200 units/kg/day is administered. Use with caution in patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, or concomitant treatment with factor VIIa. Weigh the potential benefit of treatment against the potential risk of these thromboembolic events. Monitor patients receiving &gt;100 units/kg for the development of DIC, acute coronary ischemia, and signs/symptoms of other thromboembolic events. If clinical signs/symptoms occur, discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Factor VIII: Product contains minute amounts of factor VIII which may cause an anamnestic response; anamnestic rises were not associated with reduced efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents that could transmit disease. During the manufacturing process, screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer and/or to FDA MedWatch. Patients with signs/symptoms of infection (eg, fever, chills, drowsiness) should be encouraged to consult health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX. Use of antifibrinolytics within ~6 to 12 hours after the administration of anti-inhibitor coagulant complex is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298760\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869874\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8434&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antifibrinolytic Agents: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135820\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869871\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Animal reproduction studies have not been conducted. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20547257\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if anti-inhibitor coagulant complex is present in breast milk. The manufacturer recommends that caution be exercised when administering anti-inhibitor coagulant complex to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869876\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135822\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for control of bleeding; signs/symptoms of disseminated intravascular coagulation (DIC), acute coronary ischemia, and thromboembolic events, especially if &gt;100 units/kg is administered; hemoglobin and hematocrit; hypotension; signs/symptoms of hypersensitivity reactions. <b>Note:</b> Tests used to monitor hemostatic efficacy, such as aPTT and TEG, are <b>not</b> useful for monitoring responses with anti-inhibitor coagulant complex (Hoffman 2012). Dosing to normalize these values may result in DIC.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23682864\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Multiple interactions of the components in anti-inhibitor coagulant complex restore the impaired thrombin generation of hemophilia patients with inhibitors. In vitro, anti-inhibitor coagulant complex shortens the activated partial thromboplastin time of plasma containing factor VIII inhibitor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20453114\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Peak thrombin generation: Within 15 to 30 minutes (Varadi 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 8 to 12 hours (based on thrombin generation) (Varadi 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 4 to 7 hours (based on thrombin generation) (Varadi 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13276659\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Autoplex (JP);</li>\n      <li>Autoplex-T (IL);</li>\n      <li>Feiba NF (JP);</li>\n      <li>Feiba Tim 4 (KR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23474679\"></a>Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. <i>Crit Care Med</i>, 2013;41(5):e42-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/23474679/pubmed\" target=\"_blank\" id=\"23474679\">23474679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24244342\"></a>Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. <i>PLoS One</i>. 2013;8(11):e78696.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/24244342/pubmed\" target=\"_blank\" id=\"24244342\">24244342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24508114\"></a>Faust AC, Peterson EJ. Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report. <i>J Emerg Med</i>. 2014;46(4):525-529.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/24508114 /pubmed\" target=\"_blank\" id=\"24508114 \">24508114 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FEIBA (anti-inhibitor coagulant complex) [prescribing information]. Westlake Village, CA: Baxalta US Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26714677\"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016; 24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22186946\"></a>Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. <i>Thromb Haemost</i>. 2012;107(2):253-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/22186946/pubmed\" target=\"_blank\" id=\"22186946\">22186946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25179520\"></a>Halim AB, Samama MM, Mendell J. Ex vivo reversal of the anticoagulant effects of edoxaban. <i>Thromb Res</i>. 2014;134(4):909-913.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/25179520/pubmed\" target=\"_blank\" id=\"25179520\">25179520</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/26324838/pubmed\" target=\"_blank\" id=\"26324838\">26324838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(7):2032-2060.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/26022637/pubmed\" target=\"_blank\" id=\"26022637\">26022637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. <i>J Thromb Haemost</i>. 2012;10(8):1478-1485.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/22632160/pubmed\" target=\"_blank\" id=\"22632160\">22632160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19336751\"></a>Huth-Kuhne A, Baudo F, Collins P, et al, &ldquo;International Recommendations on the Diagnosis and Treatment of Patients With Acquired Hemophilia A,&rdquo; <i>Haematologica</i>, 2009, 94(4):566-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/19336751/pubmed\" target=\"_blank\" id=\"19336751\">19336751</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23584314\"></a>Kiraly A, Lyden A, Periyanayagam U, et al, Management of hemorrhage complicated by novel oral anticoagulants in the emergency department: case report from the northwestern emergency medicine residency. <i>Am J Ther</i>. 2013;20(3):300-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/23584314 /pubmed\" target=\"_blank\" id=\"23584314 \">23584314 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lloyd Jones M, Wight J, Paisley S, et al. Control of bleeding in patients with Haemophilia A with inhibitors: a systematic review.<i>Haemophilia</i>, 2003, 9(4):464-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/12828680/pubmed\" target=\"_blank\" id=\"12828680\">12828680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ma AD and Carrizosa D, &ldquo;Acquired Factor VIII Inhibitors: Pathophysiology and Treatment,&rdquo; <i>Hematology Am Soc Hematol Educ Program</i>, 2006: 432-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/17124095/pubmed\" target=\"_blank\" id=\"17124095\">17124095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22627883\"></a>Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers [published correction appears in <i>Thromb Haemost</i>. 2013;109(1):169]. <i>Thromb Haemost.</i> 2012;108(2):217-224.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/22627883/pubmed\" target=\"_blank\" id=\"22627883\">22627883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24296541\"></a>Maurice-Szamburski A, Graillon T, Bruder N. Favorable outcome after a subdural hematoma treated with feiba in a 77-year-old patient treated by rivaroxaban. <i>J Neurosurg Anesthesiol</i>. 2014 Apr;26(2):183. doi: 10.1097/ANA.0000000000000030.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/24296541/pubmed\" target=\"_blank\" id=\"24296541\">24296541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monahan PE and Aledort LM, &ldquo;Factors Affecting Choice of Hemostatic Agent for the Hemophilia Patient With an Inhibitor Antibody,&rdquo; <i>Am J Hematol</i>, 2004, 77(4):346-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/15558804/pubmed\" target=\"_blank\" id=\"15558804\">15558804</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23666496\"></a>Neyens R, Bohm N, Cearley M, et al. Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG) to guide decision-making. <i>J Thromb Thrombolysis</i>. 2014;37(2):80-83<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/23666496 /pubmed\" target=\"_blank\" id=\"23666496 \">23666496 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24529498\"></a>Perzborn E, Heitmeier S, Laux V, Buchm&uuml;ller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. <i>Thromb Res</i>. 2014;133(4):671-681.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/24529498/pubmed\" target=\"_blank\" id=\"24529498\">24529498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14962206\"></a>Sallah S, &ldquo;Treatment of Acquired Haemophilia With Factor Eight Inhibitor Bypassing Activity,&rdquo; <i>Haemophilia</i>, 2004, 10(2):169-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/14962206/pubmed\" target=\"_blank\" id=\"14962206\">14962206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24383848\"></a>Schulman S, Ritchie B, Goy JK, Nahirniak S, Almutawa M, Ghanny S. Activated prothrombin complex concentrate for dabigatran-associated bleeding. <i>Br J Haematol</i>. 2014;164(2):308-310.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/24383848 /pubmed\" target=\"_blank\" id=\"24383848 \">24383848 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tjonnfjord GE, &ldquo;Activated Prothrombin Complex Concentrate (FEIBA&reg;) Treatment During Surgery in Patients with Inhibitors to Factor VIII/IX: The Updated Norwegian Experience, <i>Haemophilia</i>, 2004, 10(Supp 2):41-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/15385045/pubmed\" target=\"_blank\" id=\"15385045\">15385045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>J Am Coll Cardiol</i>. 2017;70(24):3042-3067. doi: 10.1016/j.jacc.2017.09.1085.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/29203195/pubmed\" target=\"_blank\" id=\"29203195\">29203195</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varadi K, Negrier C, Berntorp E, et al, &ldquo;Monitoring the Bioavailability of FEIBA With a Thrombin Generation Assay,&rdquo; <i>J Thromb Haemost</i>, 2003, 1(11):2374-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/14629472/pubmed\" target=\"_blank\" id=\"14629472\">14629472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weitz JI, Quinlan DJ, and Eikelboom JW, &ldquo;Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran,&rdquo; <i>Circulation</i>, 2012, 126(20):2428-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-drug-information/abstract-text/23147769/pubmed\" target=\"_blank\" id=\"23147769\">23147769</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8434 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10514505\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135834\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F135835\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F135851\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F135836\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F135846\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F135837\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15673193\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673194\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135824\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F135810\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573580\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F135826\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F135825\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25734780\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135816\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135828\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135813\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298760\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2869874\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135820\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2869871\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20547257\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2869876\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F135822\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F23682864\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F20453114\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F13276659\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8434|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-patient-drug-information\" class=\"drug drug_patient\">Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Patient drug information</a></li><li><a href=\"topic.htm?path=prothrombin-complex-concentrate-activated-from-human-plasma-factor-eight-inhibitor-bypassing-activity-feiba-pediatric-drug-information\" class=\"drug drug_pediatric\">Prothrombin complex concentrate, activated, from human plasma (factor eight inhibitor bypassing activity [FEIBA]): Pediatric drug information</a></li></ul></div></div>","javascript":null}